12:00 AM
 | 
Jun 10, 2002
 |  BioCentury  |  Finance

More European M & A

For the third week running, European companies did a bit of consolidating. Danish cancer play TopoTarget A/Sand U.K. cancer play Prolifix Ltd. said they will merge in a cash and stock transaction. The move follows on the announced combination of vaccine plays Berna Biotech Ltd. (SWX:BBIN, Berne, Switzerland) and Rhein Biotech N.V. (NMarkt:RBO, Maastricht, the Netherlands), and the acquisition of GenoVision AS (Oslo, Norway) by supplier Qiagen N.V. (NMarkt:QIA;...

Read the full 341 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >